IGI Logo

Bharat Parenterals is currently trading at Rs. 1805.30, up by 75.00 points or 4.33% from its previous closing of Rs. 1730.30 on the BSE.

The scrip opened at Rs. 1775.40 and has touched a high and low of Rs 1,805.30 and Rs. 1749.05 respectively. So far 188 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2274.10 on 28-Sep-2026 and a 52 week low of Rs. 880.25 on 30-Mar-2026.

Last one week high and low of the scrip stood at Rs. 1,907.10 and Rs. 1725.65 respectively. The current market cap of the company is Rs. 1231.56 crore.

The promoters holding in the company stood at 67.20%, while Institutions and Non-Institutions held 1.40% and 31.40% respectively. 

Bharat Parenterals’ material subsidiary -- Innoxel Lifesciences (Innoxel) has commenced commercial supply to the U.S. market with the launch of its first contract manufacturing (CMO) product. Manufactured by Innoxel under a CMO arrangement, the product was launched in the U.S. market by its sponsor partner on October 20, 2026, the auspicious day of Vijayadashami.

The sponsor selected Innoxel as its manufacturing partner for the product, and Auxilla Pharmaceuticals and Research LLP served as the development partner. The product is made at Innoxel's finished dosage facility in Vadodara, Gujarat, which received an Establishment Inspection Report (EIR) from the U.S. FDA in July 2025 and an EU-GMP certificate covering all four of its lines in March 2026. The identity of the sponsor and details of the product are not being disclosed in line with confidentiality obligations.

The launch is the first of the two CMO products the Company expects to commercialise in FY27. It also changes the make-up of Innoxel's revenue. All of Innoxel's FY26 revenue of Rs 72.4 crore came from licensing, of which Rs 17.1 crore was upfront and Rs 55.3 crore milestone-linked. Commercial supply adds a recurring line on top of that base, earned on every batch shipped to partners selling in the U.S.